Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?
- PMID: 27587361
- PMCID: PMC5574160
- DOI: 10.1136/gutjnl-2016-312492
Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?
Keywords: CHOLANGIOCARCINOMA; PRIMARY SCLEROSING CHOLANGITIS.
Conflict of interest statement
Comment on
-
Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.Gut. 2017 Jan;66(1):137-144. doi: 10.1136/gutjnl-2016-311739. Epub 2016 Jul 12. Gut. 2017. PMID: 27406039
References
-
- Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013;62:122–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous